Effects of Selective Inhibition of PDE4 by YM976 on Airway Reactivity and Cough in Ovalbumin-Sensitized Guinea Pigs

  • J. MokrýEmail author
  • A. Urbanová
  • I. Medvedová
  • M. Kertys
  • P. Mikolka
  • P. Kosutová
  • D. Mokrá
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 921)


Phosphodiesterases (PDEs) are enzymes involved in the degradation of cAMP and cGMP. Selective PDE4 inhibitors (e.g., roflumilast) are effective in therapy of chronic obstructive pulmonary disease associated with neutrophil inflammation. The aim of this study was to evaluate the effects of a selective PDE4 inhibitor, YM976, on citric acid-induced cough, in vivo and in vitro airway smooth muscle reactivity to histamine, and on inflammatory mediators in ovalbumin-sensitized guinea pigs, with experimentally induced eosinophil inflammation. The YM976 was administered intraperitoneally at a dose of 1.0 mg/kg once daily for 7 days. Sensitization with ovalbumin led to a significant increase in the number of coughs, and in vivo and in vitro airway reactivity. Also, increased plasma levels of IL-4, IL-5, and PAF were observed, with a significant increase in the differential count of eosinophils in both blood and bronchoalveolar lavage fluid. The YM976 suppressed the number of coughs, the airway reactivity in tracheal tissue strips, and the IL-4 level. The findings indicate that PDE4 inhibition by YM976 exerts antitussive and anti-inflammatory effects in guinea pigs with ovalbumin-induced eosinophilic inflammation.


Airway reactivity Animal model Citric acid Histamine Inflammation Interleukins Organ bath Phosphodiesterase inhibitors 



We thank K. Jesenska for technical assistance. This study was supported in parts by VEGA grant 1/0260/14, Slovak Research and Development Agency under the contract no. APVV-0305-12, grant MZ2012/35-UKMA-12, and by the project “Biomedical Center Martin” ITMS code: 26220220187, the project is co-financed from EU sources.

Conflicts of Interest

The authors declare no conflicts of interest in relation to this article.


  1. Abbott-Banner KH, Page CP (2014) Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. Basic Clin Pharmacol Toxicol 114:365–376CrossRefPubMedGoogle Scholar
  2. Aoki M, Fukunaga M, Kitagawa M, Hayashi K, Morokata T, Ishikawa G, Kubo S, Yamada T (2000a) Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets. J Pharmacol Exp Ther 295:1149–1155PubMedGoogle Scholar
  3. Aoki M, Kobayashi M, Ishikawa J, Saita Y, Terai Y, Takayama K, Miyata K, Yamada T (2000b) A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther 295:255–260PubMedGoogle Scholar
  4. Aoki M, Fukunaga M, Sugimoto T, Hirano Y, Kobayashi M, Honda K, Yamada T (2001a) Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 298:1142–1149PubMedGoogle Scholar
  5. Aoki M, Yamamoto S, Kobayashi M, Ohga K, Kanoh H, Miyata K, Honda K, Yamada T (2001b) Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. J Pharmacol Exp Ther 297:165–173PubMedGoogle Scholar
  6. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520CrossRefPubMedGoogle Scholar
  7. Christensen I, Miskovicova H, Porvaznik I, Joskova M, Mokra D, Mokry J (2012) Selective inhibition of phosphodiesterase 7 (PDE7) by BRL50481 in healthy and ovalbumin-sensitized guinea pigs. Acta Medica Martiniana 12:16–23CrossRefGoogle Scholar
  8. Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P (2010) Roflumilast. Nat Rev Drug Discov 9:761–762CrossRefPubMedGoogle Scholar
  9. Franová S, Nosalova G, Pechanova O, Sutovska M (2007) Red wine polyphenolic compounds inhibit tracheal smooth muscle contraction during allergen-induced hyperreactivity of the airways. J Physiol Pharmacol 59:727–732Google Scholar
  10. Fujimura M, Liu Q (2007) Selective inhibitors for phosphodiesterase 3 and 4 in antigen-induced increase of cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther 20:543–548CrossRefPubMedGoogle Scholar
  11. Giembycz MA, Field SK (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. J Drug Des Devel Ther 4:147–158Google Scholar
  12. Gupta S (2012) Side-effects of roflumilast. Lancet 379:710–711CrossRefPubMedGoogle Scholar
  13. Karish SB, Gagnon JM (2006) The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 40:1096–1104CrossRefPubMedGoogle Scholar
  14. Kitta T, Tanaka H, Mitsui T, Moriya K, Nonomura K (2008) Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation. Br J Urol Int 102:1472–1476Google Scholar
  15. Medvedová I, Prso M, Eichlerova A, Mokra D, Mikolka P, Mokry J (2015) Influence of roflumilast on airway reactivity and apoptosis in ovalbumin-sensitized guinea pigs. Adv Exp Med Biol 838:11–18CrossRefPubMedGoogle Scholar
  16. Mokrý J, Mokra D (2013) Immunological aspects of phosphodiesterase inhibition in the respiratory system. Respir Physiol Neurobiol 187:11–17CrossRefPubMedGoogle Scholar
  17. Mokrý J, Nosalova G (2011) The influence of the PDE inhibitors on cough reflex in guinea pigs. Bratisl Lek Listy 112:131–135PubMedGoogle Scholar
  18. Mokrý J, Mokra D, Nosalova G, Beharkova M, Feherova Z (2008) Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 59:473–482PubMedGoogle Scholar
  19. Mokrý J, Nosalova G, Mokra D (2009) Influence of xanthine derivatives on cough and airway reactivity in guinea pigs. J Physiol Pharmacol 60:87–91PubMedGoogle Scholar
  20. Mokrý J, Joskova M, Mokra D, Christensen I, Nosalova G (2013) Effects of selective inhibition of PDE4 and PDE7 on airway reactivity and cough in healthy and ovalbumin-sensitized guinea pigs. Adv Exp Med Biol 756:57–64CrossRefPubMedGoogle Scholar
  21. Moriuchi H, Nakahara T, Maruko T, Sakamoto K, Ishii K (2003) Relaxant effect of YM976, a novel phosphodiesterase 4 inhibitor, on bovine tracheal smooth muscle. Eur J Pharmacol 470:57–64CrossRefPubMedGoogle Scholar
  22. Morjaria JB, Dickinson RS, Morice AH (2013) Novel antitussive strategies. Drug Discov Today 18:380–388CrossRefPubMedGoogle Scholar
  23. Nosalová G, Mokrý J (2001) The mechanism of action of xanthine derivatives and suppression of cough. Acta Medica Martiniana 1:14–18Google Scholar
  24. Page CP, Spina D (2012) Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12:275–286CrossRefPubMedGoogle Scholar
  25. Sutovska M, Franová S, Sutovsky J (2009) The influence of animal species on the relationship between ATP-sensitive potassium ion channels and defense reflexes of the airways. Bratisl Lek Listy 110:269–275PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • J. Mokrý
    • 1
    Email author
  • A. Urbanová
    • 1
  • I. Medvedová
    • 1
  • M. Kertys
    • 1
  • P. Mikolka
    • 2
  • P. Kosutová
    • 2
  • D. Mokrá
    • 2
  1. 1.Biomedical Center (BioMed) Martin, Division of Respirology and Department of Pharmacology, Jessenius School of Medicine in MartinComenius University in BratislavaMartinSlovakia
  2. 2.Biomedical Center (BioMed) Martin, Division of Respirology and Department of Physiology, Jessenius School of Medicine in MartinComenius University in BratislavaMartinSlovakia

Personalised recommendations